Mixed amphetamine salts: Difference between revisions
From Pharmacopedia
More actions
| [pending revision] | [pending revision] |
Terminology sweep (site-wide): drug/medication → medicine |
Terminology: medicine → med (shorter form per user preference) |
||
| Line 17: | Line 17: | ||
| mechanism = TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport — net release of dopamine and norepinephrine | | mechanism = TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport — net release of dopamine and norepinephrine | ||
| intro = '''Mixed amphetamine salts (MAS)''' — marketed primarily as '''Adderall''' — is a 3:1 mixture of dextroamphetamine and levoamphetamine salts (dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate). | | intro = '''Mixed amphetamine salts (MAS)''' — marketed primarily as '''Adderall''' — is a 3:1 mixture of dextroamphetamine and levoamphetamine salts (dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate). | ||
Amphetamine was first synthesized in 1887 by Lazăr Edeleanu, then developed as a | Amphetamine was first synthesized in 1887 by Lazăr Edeleanu, then developed as a med in the late 1920s. "Adderall" was approved by the FDA in 1996, and has since become one of the most popular meds in the United States. Adderall/MAS is FDA-approved for attention-deficit hyperactivity disorder and narcolepsy. It is listed in Schedule II of the Controlled Substances Act, and so is tightly regulated in the United States as well as many other countries around the world. | ||
| indications = <indication ref="adhd" author="MDElliottMD"/> | | indications = <indication ref="adhd" author="MDElliottMD"/> | ||
<indication ref="narcolepsy" author="MDElliottMD"/> | <indication ref="narcolepsy" author="MDElliottMD"/> | ||
| Line 99: | Line 99: | ||
| monitoring = * Baseline: cardiovascular history, weight/height, mental health history (especially for psychosis/bipolar/substance use risk), (optional) blood pressure, (optional) heart rate, | | monitoring = * Baseline: cardiovascular history, weight/height, mental health history (especially for psychosis/bipolar/substance use risk), (optional) blood pressure, (optional) heart rate, | ||
* At each visit: efficacy, side effects, general well-being | * At each visit: efficacy, side effects, general well-being | ||
* Periodically reassess continued need; consider | * Periodically reassess continued need; consider med holidays to assess ongoing benefit | ||
* Sleep quality (insomnia is dose-limiting) | * Sleep quality (insomnia is dose-limiting) | ||
| counseling = * Take first thing in the morning to minimize insomnia; avoid (late) afternoon dosing. | | counseling = * Take first thing in the morning to minimize insomnia; avoid (late) afternoon dosing. | ||